Canada approves adalimumab biosimilars Simlandi and Yuflyma

Biosimilars/News | Posted 21/01/2022 post-comment0 Post your comment

Canada’s drug regulator, Health Canada, has approved the adalimumab biosimilars Simlandi (AVT02) and Yuflyma (CT-P17).

Adalimumab V13F21

The drugs are biosimilars of AbbVie’s Humira (adalimumab). Adalimumab is a human monoclonal antibody that treats autoimmune diseases by inhibiting tumour necrosis factor (TNF), a soluble inflammatory cytokine. Adalimumab binds to TNF-alpha (TNF-α), preventing it from activating TNF receptors, which cause the inflammatory reactions associated with autoimmune diseases. Adalimumab is indicated for the treatment of rheumatoid, juvenile idiopathic and psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, psoriasis and ulcerative colitis.

Both Simlandi and Yuflyma are high-concentration, citrate-free biosimilars to Humira, which is used to treat a range of certain inflammatory conditions.

Simlandi is a result of the collaboration between Iceland-based biosimilars maker Alvotech and Canada-base pharmaceutical company JAMP Pharma Group (JAMP). The two companies signed an exclusive agreement to collaborate on a broad portfolio of biosimilars in January 2020 [1].

Simlandi was approved on 5 January 2022 as a high-concentration biosimilar to Humira at doses of 40 mg/0.4 mL and 80 mg/0.8 mL. Health Canada has also ruled that the 40 mg/0.4 mL and 80 mg/0.8 mL presentations of Simlandi are not subject to the 24-month statutory stay pursuant to the Patented Medicines (Notice of Compliance) Regulations because AbbVie Corporation, the marketer of Humira, elected to not market the equivalent high-concentration versions to Canadian patients. This clears the way for JAMP to launch Simlandi in the Canadian market.

Yuflyma is produced by South Korean biotechnology company Celltrion. It was approved on 24 December 2021 as a high-concentration biosimilar to Humira at a dose of 100 mg/mL.

This is the first biosimilar approval in Canada for JAMP. For Celltrion, on the other hand, this marks the fifth biosimilar approval. The company has already received Canadian approval for trastuzumab (Herzuma), infliximab (Remsima and Remsima SC), and rituximab (Truxima) biosimilars. These latest approvals bring the total number of adalimumab biosimilars approved in Canada to nine [2].

Related articles
Canada approves filgrastim and insulin aspart biosimilars Nypozi and Kirsty

Canada approves adalimumab and bevacizumab biosimilars


The new section of the ‘Latin American Forum’ on GaBI has been launched. The objective of this new section is to provide you with all the latest news and updates on developments of generic and biosimilar medicines in Latin America in Spanish.

View last week’s headline article: Diferencias en estudios clínicos y farmacovigilancia de medicamentos biológicos en América Latina

Browse the news in the Latin American Forum!

Register to receive the GaBI Latin American Forum newsletter. Inform colleagues and friends of this new initiative.


Se ha lanzado la nueva sección del ‘Foro Latinoamericano’ sobre GaBI. El objetivo de esta nueva sección es brindarle las últimas noticias y actualizaciones sobre desarrollos de medicamentos genéricos y biosimilares en América Latina en español.

Vea el artículo principal de la semana pasada: Diferencias en estudios clínicos y farmacovigilancia de medicamentos biológicos en América Latina

Explore las noticias en el Foro Latinoamericano!

Regístrese para recibir el boletín informativo GaBI Foro Latinoamericano. Informe a colegas y amigos sobre esta nueva iniciativa. 


1. GaBI Online - Generics and Biosimilars Initiative. New biosimilars partnerships from Alvotech and Biocon biosimilar from Samsung Bioepis []. Mol, Belgium: Pro Pharma Communications International; [cited 2022 Jan 21]. Available from:
2. GaBI Online - Generics and Biosimilars Initiative. Biosimilars approved in Canada []. Mol, Belgium: Pro Pharma Communications International; [cited 2022 Jan 21]. Available from:

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2022 Pro Pharma Communications International. All Rights Reserved.

Source: Alvotech, Health Canada

comment icon Comments (0)
Post your comment
Related content
Most viewed articles
About GaBI
Home/About GaBI Posted 06/08/2009
EU guidelines for biosimilars
EMA logo 1 V13C15
Home/Guidelines Posted 08/10/2010